AgomAb Therapeutics is a biopharmaceutical organization developing agonist antibodies to regenerate damaged tissue. It mainly develops antibodies for fibrosis, inflammation, autoimmunity and degenerative diseases, and applies the products to clinical trials. A few days ago, Agomab Therapeutics announced the completion of the B+ round of financing and received $40.5 million in funding support. Pfizer led the expansion financing through its Pfizer Breakthrough Growth Initiative. Together with the initial stage funding, the total Series B financing reached $114 million.
This article is reproduced from: https://www.itjuzi.com/investevent/13370904
This site is for inclusion only, and the copyright belongs to the original author.